IXICO announces updates to client contracts

£2.4 million expansion of study programmes with two large pharma client contracts

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces:

- £1.8 million extension to a Phase III study in Huntington's Disease (HD), previously announced in September 2018

- £0.6 million extension to a study programme in Progressive Supranuclear Palsy (PSP), previously announced in October 2019

Giulio Cerroni, Chief Executive Officer of IXICO, commented:

"HD and PSP are devastating neurological conditions, currently with no cure, and we are pleased to build momentum in our mission to support our clients in delivering data analytics in these challenging areas of rare, neurodegenerative disease. Our services will enable them to measure the impact of the trialled drugs with greater confidence and potentially unlock new insights into disease progression.

"Following the recent announcement of our strong trading results for FY19, the expansion of these work programmes for two large pharma clients is further evidence of the value that we deliver through our proprietary AI data analytics and our ability to scale our operations to meet increasing size and complexity of clinical trials as they progress through clinical development."

 

For further information please contact:

IXICO plc

+44 (0) 20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 

   

Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0) 20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)

 

Michael F Johnson / Russell Kerr (Sales)

 

   

Optimum Strategic Communications

 +44 (0) 203 950 9144

Mary Clark, Supriya Mathur, Manel Mateus

 

IXICO@optimumcomms.com

 

About IXICO

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.

Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.


Date: 23/12/2019